# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11...
The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was...
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immu...
ANKTIVA® Drug Substance completed and released with two-year storage stability data sufficient for 170,000 doses of ANKTIVA pro...